EVALUATION OF THE EFFICACY OF ANTI-PD-L1 IMMUNOTHERAPY IN NON-MICROCRITICAL LUNG CANCER IN CLINICAL PRACTICE
4CPS-270
RESULTS OF EFFECTIVENESS AND SAFETY IN REAL CLINICAL PRACTICE OF NIVOLUMAB, PEMBROLIZUMAB AND ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER
4CPS-269
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ASSOCIATED WITH CYTOREDUCTIVE SURGERY IN PERITONEAL CANCER TREATMENTS: A MULTIDISCIPLINARY EXPERIENCE TO EVALUATE ITS EFFICACY
4CPS-268
NIVOLUMAB VERSUS PEMBROLIZUMAB IN SECONDLINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER IN CLINICAL PRACTICE
4CPS-267
RETROSPECTIVE ANALYSIS OF CARBOPLATIN DOSING PRESCRIBED IN A CHEMOTHERAPY REGIMEN AND ITS RELATIONSHIP WITH TOXICITY
4CPS-266
AFATINIB AS FIRSTLINE TREATMENT FOR ADVANCED LUNG ADENOCARCINOMA IN A PATIENT HARBOURING EXON 19 DELETION IN EGFR: A CASE REPORT
4CPS-265
CEMIPLIMAB FOR THE TREATMENT OF RELAPSE OF A CUTANEOUS SQUAMOUS CELL CARCINOMA IN AN ADULT PATIENT: A CASE REPORT
4CPS-264
AUTOIMMUNE MYOPATHY RESULTING FROM A THERAPY WITH NIVOLUMAB FOR METASTATIC NON-SMALL CELL LUNG CANCER: A CASE REPORT
4CPS-263
CASE REPORT OF KAWASAKI DISEASE AND SARS-COV-2 INFECTION IN A PAEDIATRIC HOSPITAL
4CPS-262
CLINICAL EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGY: A RETROSPECTIVE COHORT STUDY AT THE MATER MISERICORDIAE UNIVERSITY HOSPITAL
4CPS-261
USE OF INTRAVENOUS IMMUNOGLOBULIN: BY THE BOOK?
4CPS-260
ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION
4CPS-259
ONE YEAR WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
4CPS-258
EVALUATION OF MEDICINES ADHERENCE AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B
4CPS-257
RELEVANCE OF RITONAVIR INTERACTIONS IN HIV TREATMENTS THAT INVOLVE TREATMENT MODIFICATION
